Ask about this productRelated genes to: CD44 antibody
- Gene:
- CD44 NIH gene
- Name:
- CD44 molecule (Indian blood group)
- Previous symbol:
- MIC4, MDU2, MDU3
- Synonyms:
- IN, MC56, Pgp1, CD44R, HCELL, CSPG8
- Chromosome:
- 11p13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2019-04-23
Related products to: CD44 antibody
Related articles to: CD44 antibody
- Cancer stem cells (CSCs) are intrinsically resistant to conventional therapies and play a pivotal role in cancer metastasis and recurrence. Eradication of CSCs requires combination strategies that simultaneously target multiple pathways at therapeutical concentrations throughout tumours. This study investigated the potential of a fusogenic pH-sensitive liposomal (pSL) nanococktail comprising doxorubicin and bufalin for targeting CSCs in clinically relevant HER2-positive breast cancer models, including cell lines (CD44 HCC1954 and CD44 BT474), homotypic and heterotypic spheroids, patient-derived organoids, and orthotopic HCC1954 mouse xenografts. At the optimal doxorubicin: bufalin ratio (10:1), the pSL-cocktail demonstrated pronounced synergistic efficacy and significantly outperformed all control formulations, including monodrug-loaded pSLs, non-pH-sensitive (DOXIL-like) liposomes, and free drugs. It significantly suppressed tumour proliferation and stemness, including CSC-associated migration, mammosphere formation, and self-renewal. In spheroids, the nanococktail rapidly penetrated to the spheroid core (≥100 µm within 1 h) and suppressed invasive dissemination. Similarly, it disrupted patient-derived organoids, achieving > 90% reduction in ATP levels and > 90% cell death. In vivo, the pSL-cocktail was well-tolerated and achieved significant tumour shrinkage, whereas DOXIL-like liposomes and free drugs showed minimal activity or severe adverse effects. Overall, this pSL-cocktail demonstrates strong potential for CSC-elimination and tumour clearance through synergistic drug combination, superior tumour penetration, and endosomal pH-triggered intracellular drug release. - Source: PubMed
Publication date: 2026/05/28
Ahmed Kamel SNolan EmmaWang JingjingJamieson Stephen M FPan PatrickMao DengxuanPorter DavidLaking GeorgeFeng NianpingShelling Andrew NWu Zimei - Cervical adenocarcinoma is an increasingly common and aggressive subtype of cervical cancer with marked biological heterogeneity. Accumulating evidence suggests that HPV-positive and HPV-negative adenocarcinomas exhibit distinct immune microenvironments, but the underlying mechanisms remain unclear. - Source: PubMed
Publication date: 2026/05/13
Zhang JianingWei WenjuanZhang YajunWang Daqing - Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, oxidative stress damage and joint destruction. Current treatments often face challenges including limited targeting efficacy and systemic side effects. To develop a novel targeted therapy for RA, this study constructed a functionalized extracellular vesicle (EV) system by engineering ginseng stems and leaves-derived EVs with hyaluronic acid (HA) modification and curcumin (Cur) loading (Cur@EVs-PH). Structurally, the EVs-PH drug-loaded nanoplatform integrates the remarkable anti-inflammatory and antioxidant properties of EVs with the prolonged circulation capacity conferred by PEG. This design further capitalizes on the targeting ability of HA, thereby providing a robust structural foundation for the efficient delivery of therapeutics to disease sites. Our results demonstrated that the designed system achieved enhanced inflammatory targeting through CD44 receptor-mediated accumulation and exhibited potent anti-inflammatory and antioxidant activities. In the collagen-induced arthritis model, Cur@EVs-PH significantly alleviated joint swelling, reduced pathological scores and normalized immune organ indices. Mechanistic studies revealed that the therapeutic effects were mediated through suppression of pro-inflammatory cytokines and promotion of macrophage M2 polarization. This integrated strategy combining natural EVs, targeted modification and active drug loading provides a promising platform for the treatment of RA and other inflammatory diseases. - Source: PubMed
Publication date: 2026/04/26
Zhang ChuanjieWang YingjieJiang XiaoyuWang DakeYuan YajiangLi JianyeGao WeiranJiang HousenMei Xifan - Secreted phosphoprotein 1 (SPP1) has been implicated in various tumors and is known to correlate with immune infiltration and poor prognosis. However, its functional role as an immune communication mediator within the lung adenocarcinoma (LUAD) tumor microenvironment (TME) remains poorly defined. This study aimed to investigate the prognostic value of SPP1 and its association with inferred intercellular communication patterns in LUAD. - Source: PubMed
Publication date: 2026/05/28
Jiao LijunXu XiantaoLiu YantongLi FeifeiShi Jia-Xin - Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options, making it difficult to manage effectively. This study investigates the anticancer potential of eco-friendly zinc oxide nanoparticles (SO-ZnO NPs), synthesized using Saccharum officinarum (jaggery) extract, against MDA-MB-231 breast cancer cells. The NPs were characterized by various techniques, confirming their spherical morphology, a primary particle size of 20-50 nm, aggregation into larger clusters (100-250 nm), and a moderately positive surface charge. The composition was predominantly zinc (96.1%), oxygen (2.3%), and carbon (1.59%), attributed to bioorganic capping agents. SO-ZnO NPs showed significant anticancer effects, with an IC50 of 125.00 ± 2.60 µg/mL, indicating potent cytotoxicity above this concentration. They also suppressed key inflammatory markers (IL-6 secretion and mRNA expression) and inhibited the proliferation of cancer stem cells. Notably, SO-ZnO NPs downregulated stemness markers (NANOG, OCT4, CD44) and disrupted mammosphere formation, suggesting a potential to target cancer stem cell self-renewal and modulate the tumor microenvironment. These findings underline the therapeutic potential of SO-ZnO NPs in treating TNBC, though further in vivo studies are necessary to evaluate their safety and clinical effectiveness. - Source: PubMed
Publication date: 2026/05/28
Farooqi Muhammad AwaisKim Kyeoung CheolKim Ji-HyangShamamedov DovranFarooqi Hafiz Muhammad UmerKang Chul Ung